Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

The gross carrying amounts and net book value of our intangible assets are as follows:

		December 31, 2021
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization		Accumulated Impairment Charges		Net Book Value
Ryanodex intangible	18.5	$	15,000	$	(5,079)	$	—	$	9,921
Developed technology	5	8,100		(8,100)		—		—
Vasopressin Milestone	1	750		—		—		750
Total		$	23,850	$	(13,179)	$	—	$	10,671

		December 31, 2020
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization		Accumulated Impairment Charge		Net Book Value
Ryanodex intangible	20	15,000		(3,500)		—		11,500
Developed technology	5	8,100		(6,683)		—		1,417
Total		$	23,100	$	(10,183)	$	—	$	12,917

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Based on definite-lived intangible assets recorded as of December 31, 2021, and assuming that the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses are estimated as follows:

	Estimated Amortization Expense
Year Ending December 31,
2022	3,073
2023	2,785
2024	2,511
2025	2,302
All other	—
Total estimated amortization expense	$	10,671